A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

Inclusion Criteria:

• Participants who are overtly healthy as determined by medical history and physicalexamination.

• Have a stable body weight for one month prior to screening (less than or equal to 5percent body weight gain or loss) and Body Mass Index (BMI) in range of 27 to 40kilogram per meter square (kg/m²).

• Participants must be reliable and willing to make themselves available for theduration of the study and are willing to follow study procedures.

• Have venous access sufficient to allow for blood sampling.

Exclusion Criteria:

• Have hemoglobin A1c (HbA1c) level of 6.5 percent (%) or greater.

• Have a history of current cardiovascular, respiratory, hepatic, renal,gastrointestinal, endocrine, hematological, or neurological disorders or othersignificant active, uncontrolled medical conditions.

• Have significant history of or currently have major depressive disorder orpsychiatric disorder within the last 2 years.

• Obesity induced by other endocrine disorders, such as Cushing's syndrome orPrader-Willi syndrome.

• Have known clinically significant gastric emptying abnormality.

• Have undergone bariatric surgery (for example: Lap-Band, Gastric Bypass)

• Have a known self or family history (first-degree relative) of multiple endocrineneoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or any form of thyroidcancer.

• Have an abnormal 12-lead electrocardiogram (ECG) at screening.

• Have history of pancreatitis.

• Judged by the study investigator to be at serious suicidal risk and have answered "Yes" to either question 4 or 5 on the Columbia-Suicide Severity Rating Scale [C-SSRS]).

• Have difficulty swallowing capsules or tablets.